<DOC>
	<DOCNO>NCT00947167</DOCNO>
	<brief_summary>To determine objective response rate ( RR ) RECIST guideline version 1.1 patient treated strategy consist initial therapy pertuzumab single agent addition erlotinib stable disease progressive disease three month ( Simon design ) .</brief_summary>
	<brief_title>A Phase II Study Pertuzumab Erlotinib Metastatic Unresectable Neuroendocrine Tumors</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Neuroendocrine Tumors</mesh_term>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<mesh_term>Adenoma , Islet Cell</mesh_term>
	<mesh_term>Endocrine Gland Neoplasms</mesh_term>
	<mesh_term>Multiple Endocrine Neoplasia</mesh_term>
	<mesh_term>Adrenal Gland Neoplasms</mesh_term>
	<mesh_term>Pertuzumab</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Subjects must treat Stanford University Medical Center entire length study participation . 1 . Patients must histologically cytologically confirm welldifferentiated neuroendocrine tumor . Patients must deem unresectable due involvement critical vasculature adjacent organ invasion metastatic disease . 2 . Patients prior surgical resection develop radiological clinical evidence metastatic cancer require separate histological cytological confirmation metastatic disease unless interval &gt; 5 year elapse primary surgery development metastatic disease . Clinicians consider biopsy lesion establish diagnosis metastatic disease substantial clinical ambiguity regard nature source apparent metastasis . 3 . Prior chemotherapy permit . 4 . Prior concurrent somatostatin analogue use permit . 5 . Patients must primary metastatic lesion measurable least one dimension Modified RECIST criterion ( v1.1 ) within 4 week prior entry study . 6 . Patients must ECOG performance status 02 . 7 . Patients must &gt; = 18 year age . 8 . Laboratory value &lt; = 2 week prior randomization : Absolute Neutrophil Count ( ANC ) &gt; = 1.5 x 109/L ( &gt; = 1500/mm3 ) Platelets ( PLT ) &gt; = 50 x 109/L ( &gt; = 100,000/mm3 ) ( &gt; = 25 x 109/L ( &gt; = 100,000/mm3 ) thrombocytopenia secondary nonmyelosuppressive cause splenic sequestration ) . Hemoglobin ( Hgb ) &gt; = 9 g/dL Serum creatinine &lt; = 1.5 x ULN Serum bilirubin &lt; = 1.5 x ULN ( &lt; = 3.0 x ULN liver metastasis present ) Aspartate aminotransferase ( AST/SGOT ) , alanine aminotransferase ( ALT/SGPT ) &lt; = 3.0 x ULN ( &lt; = 5.0 x ULN liver metastasis present ) . Note : ERCP percutaneous stenting may use normalize liver function test . Albumin &gt; = 1.5 9 . LVEF TTE MUGA &gt; = 50 % 10 . Life expectancy &gt; = 12 week 11 . Ability give write informed consent accord local guideline 1 . DiseaseSpecific Exclusions 1 . Prior full field radiotherapy &lt; = 4 week limited field radiotherapy &lt; = 2 week prior enrollment . Patients must recover therapyrelated toxicity . The site previous radiotherapy evidence progressive disease site disease . 2 . Prior biologic immunotherapy &lt; = 2 week prior registration . Patients must recover therapyrelated toxicity 3 . If history primary cancer , subject eligible : Curatively resect nonmelanomatous skin cancer Curatively treat cervical carcinoma situ Other primary solid tumor curatively treat know active disease present treatment administer last 3 year 4 . Concurrent use investigational agent patient receive investigational drug &lt; = 4 week prior enrollment . 2 . General Medical Exclusions 1 . Subjects know chronic active hepatitis B C infection impair hepatic function ( ineligible AST ALT &gt; 3.0 x ULN ) . 2 . History medical psychiatric condition laboratory abnormality opinion investigator may increase risk associate study participation study drug administration may interfere conduct study interpretation study result 3 . Male subject willing use adequate contraception upon enrollment study 6 month follow last dose secondline treatment 4 . Female subject ( childbearing potential , postmenopausal le 6 month , surgically sterilize , abstinent ) willing use oral , patch implant contraceptive , doublebarrier birth control , IUD course study 6 month follow last dose secondline treatment 5 . Female subject breastfeed positive serum pregnancy test 72 hour prior randomization 6 . Pleural effusion ascites cause respiratory compromise ( &gt; = CTCAE grade 2 dyspnea ) 7 . Any following concurrent severe and/or uncontrolled medical condition within 24 week enrollment could compromise participation study : Unstable angina pectoris Symptomatic congestive heart failure Myocardial infarction &lt; = 6 month prior registration and/or randomization Serious uncontrolled cardiac arrhythmia Uncontrolled diabetes Active uncontrolled infection Interstitial pneumonia extensive symptomatic interstitial fibrosis lung Chronic renal disease 8 . Patients unwilling unable comply protocol 9 . Life expectancy le 12 week 10 . Current , recent ( within 4 week first infusion study ) , plan participation experimental drug study Genentechsponsored cancer study</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>